Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
featured
A Phase III study of the Efficacy and Safety of subjects with Moderately to Severe active Rheumatoid Arthritis which have been inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) inhibitor therapy

A Phase III study of the Efficacy and Safety of subjects with Moderately to Severe active Rheumatoid Arthritis which have been inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) inhibitor

  • 302 views
  • 25 Mar, 2021
  • 1 location
featured
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

  • 2362 views
  • 23 Nov, 2020
  • 18 locations
Genetic Polymorphisms of TNF- Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease

contribute to disease severity. Cytokine gene polymorphism has been regarded affecting prognosis of disease. By detecting HBV genotyping and tumor necrosis factor-alpha polymorphism, this study

carcinoma
hepatitis
hepatocellular carcinoma
cirrhosis
tumor necrosis factor-alpha
  • 0 views
  • 07 Nov, 2020
  • 1 location
Topical Infliximab for Sterile Corneal Melt

necrolysis or mucous membrane pemphigoid. Infliximab is an antibody against tumour necrosis factor alpha and has been used to treat or prevent corneal melt in certain patients with inflammatory of

  • 3 views
  • 03 Feb, 2021
  • 2 locations
Impact of Sacroiliac Joint Injection on Bone Marrow Edema

necrosis factor alpha (TNF) inhibitor and anti-interleukin 17 have shown promising results in achieving remission or low disease activity for axial SpA . Magnetic resonance imaging (MRI) is

  • 0 views
  • 30 May, 2021
  • 1 location
Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

In this phase II study, the investigators are aiming to explore lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)

  • 1 views
  • 23 Jan, 2021
  • 1 location
An Explorative Psoriasis Biomarker Study

Plaque psoriasis may be an ideal model disease to explore potential therapeutic effects of immunosuppressive agents, given the easy accessibility of inflammatory lesions. In this study, the applicability of a systems dermatology approach is investigated in order to better assess the efficacy of psoriasis treatments at an early clinical stage. …

  • 0 views
  • 24 Jun, 2021
  • 1 location
Effects of Microbouts of Activity on Metabolic Health

Population studies suggest that time spent in sedentary behaviors is associated with all-cause mortality including obesity, diabetes, and cardiovascular diseases, independent of time spent in exercise. Frequent interruptions to sedentary time are however beneficially associated with metabolic health outcomes, even in individuals who exercise regularly. The goal is to use …

  • 3 views
  • 20 Feb, 2021
  • 1 location
Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia

Different types of stem cells have recently been studied in clinical trial on ischemic disease of the heart and muscular arteries. Adipose derived stem cell, have shown in vitro and in vivo models a stronger potential of success in recovering from ischemic disease and oxygenation of the tissues. The investigators …

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study

The primary objective of this study is to provide data regarding clinical and immunologic activity of oral doses of pravastatin 80mg administered daily for 6 consecutive weeks, for the treatment of active Crohn's disease as shown by the Harvey-Bradshaw Index (HBI) and/or elevated C-reactive protein (CRP). We hypothesize pravastatin will …

ciprofloxacin
prednisone
azathioprine
budesonide
mesalamine
  • 21 views
  • 07 Nov, 2020
  • 1 location